Trial Information

Summary: A Phase II, Open Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects with Stage III Melanoma

You have been asked to participate in this research study because you have been diagnosed with melanoma that was discovered in your lymph nodes and has been surgically removed.  The purpose of this study is to see whether treatment with an experimental immunotherapy called Transgenic Lymphocyte Immunization (TLI) is safe and effective in helping the immune system develop a response against melanoma cells. Treatment on this study will last for about three months. After your treatment on this study is complete, your condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:59 PM